1620097-07-5

Basic information

• Product Name: Suvorexant intermediate
• Synonyms: (R)-(4-Benzyl-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone;[(7R)-Hexahydro-7-methyl-4-(phenylmethyl)-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone;(R)-(4-benzyl-7-methyl-1,4-diazepan-1-yl)(5-metyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
• CAS NO: 1620097-07-5
• Molecular Formula: C23H27N5O
• Molecular Weight: 389.49
• Mol File: 1620097-07-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 583.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.40±0.40(Predicted)
• CAS DataBase Reference: Suvorexant intermediate(CAS DataBase Reference)
• NIST Chemistry Reference: Suvorexant intermediate(1620097-07-5)
• EPA Substance Registry System: Suvorexant intermediate(1620097-07-5)

Safety Data

• Hazardous Substances Data: 1620097-07-5(Hazardous Substances Data)

Usage

General Description

The chemical "Suvorexant intermediate" is a key compound in the synthesis of Suvorexant, a medication used to treat insomnia. Suvorexant intermediate is an important intermediate in the manufacturing process of Suvorexant, and it is essential for the production of the final pharmaceutical drug. It is usually synthesized using a series of chemical reactions, and its purity and quality are crucial for the effectiveness and safety of the final product. Suvorexant intermediate plays a critical role in the pharmaceutical industry, as it is one of the key components in the production of a widely used medication for the treatment of insomnia.

Upstream product

• 1104546-96-4 5-methyl-2-(2Η-1,2,3-triazol-2-yl)benzoyl chloride 
• 170367-70-1 [1(R)-methyl-3-[(phenylmethyl)amino]propyl]carbamic acid, 1,1-dimethylethyl ester 
• 956317-36-5 2-(2H-1,2,3-triazol-2-yl)-5-methylbenzoic acid 
• 1620097-06-4 (R)-1-benzyl-5-methyl-1,4-diazepane 
• 53386-64-4 methyl 2-(benzylamino)acetate 

Downstream Products

• 1030377-32-2 1-(7(R)-methyl-1,4-diazepan-1-yl)-1-[5-methyl-2-(2H-1,2,3-triazole-2-yl)phenyl]methanone 
• 1030377-33-3 Suvorexant 

Relevant articles and documents

Preparation method of raw drug suvorexant

The invention discloses a preparation method of raw drug suvorexant. The preparation method comprises the following step of generating S1 condensation acylation reaction by virtue of an intermediate I and an intermediate II in the presence of a condensing agent so as to generate an intermediate III, wherein the condensing agent is selected from one or combination of more than two of ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N'-carbonyldiimidazole, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole and tri(2,6-dimethoxyphenyl)bismuth. By adopting the proper condensing agent or condensing agent combination in the S1 condensation acylation reaction in the preparation method, and the yield in the prior art can be achieved at a reaction temperature of about 25 DEG C, and the condensing agent and intermediate products are simply separated, so that the energy saving and the consumption reduction in the large-scale industrial production are promoted.

PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT

A novel processes for the preparation of suvorexant (formula I), its related compounds and its intermediates that are simple, economical and commercially viable. (I)

Facile synthesis of suvorexant, an orexin receptor antagonist, via a chiral diazepane intermediate

A facile synthesis of suvorexant, an orexin receptor antagonist, is described. The key intermediate 6 was prepared from R-3-aminobutyric acid through protection, condensation, deprotection, cyclization, and hydrogenation steps. The title product was obtained with a total yield of 31% (>99% ee) after eight linear steps using commercially available raw materials.